Provider Briefing: Albendazole Availability in 2026

If you've had patients report difficulty filling Albendazole prescriptions, you're seeing a pattern that has been building for years. While Albendazole is not formally listed on the FDA Drug Shortage database as of early 2026, real-world availability remains inconsistent across much of the country.

This briefing covers the current availability landscape, the factors driving supply constraints, prescribing implications, cost and access considerations, and tools you can use to help patients get treated.

Timeline: How We Got Here

Albendazole's availability challenges didn't appear overnight. Here's the key timeline:

• 2004: First documented FDA shortage of Albendazole in the U.S.
• 2009: SmithKline Beecham's brand Albenza undergoes ownership transitions, eventually landing with Amedra Pharmaceuticals.
• 2017: Second documented shortage, linked to manufacturing and raw material supply disruptions. Significant clinical impact reported.
• 2018: International shortage reported in Italy, with treatment interruptions for cystic echinococcosis patients at referral centers.
• 2019–2024: U.S. prescriptions more than double — from approximately 100,850 pills in Q1 2019 to 237,571 in Q4 2024 (a 135% increase).
• 2025–2026: No formal FDA shortage listing, but widespread reports of inconsistent pharmacy-level availability. Regional disparities persist.

Prescribing Implications

The supply dynamics around Albendazole have several practical implications for prescribers:

Verify Availability Before Prescribing

Consider checking pharmacy availability before sending a prescription. Tools like Medfinder for Providers can help identify which pharmacies in your patient's area currently stock Albendazole. This prevents the common scenario where a patient receives a prescription, drives to the pharmacy, and discovers it's not in stock.

Plan for Treatment Delays

For conditions requiring extended Albendazole courses — particularly hydatid disease (28-day cycles with 14-day drug-free intervals) — anticipate potential refill challenges. Consider:

• Prescribing the full course upfront when appropriate
• Identifying backup pharmacies early in the treatment course
• Discussing contingency plans with patients at the first visit

Document Clinical Necessity

Some insurance plans require prior authorization for Albendazole, particularly for extended courses. Document the clinical indication clearly, as this can expedite approvals and help patients navigate cost barriers.

Consider Alternatives When Appropriate

For certain infections, equally effective alternatives exist:

• Strongyloidiasis: Ivermectin is the preferred first-line treatment and is generally more available.
• Intestinal helminths (pinworm, hookworm, roundworm, whipworm): Mebendazole is a reasonable substitute, though availability can also be variable.
• Neurocysticercosis: Praziquantel can be used as an alternative or adjunct. Combination therapy (Albendazole + Praziquantel) has shown improved efficacy for multiple cysts.
• Schistosomiasis: Praziquantel remains the standard of care.

For a detailed comparison of alternatives, see our clinical resource on alternatives to Albendazole.

Current Availability Picture

Albendazole is manufactured in the U.S. by a limited number of generic companies, including Amneal Pharmaceuticals, Teva, and Lannett. The brand-name product, Albenza, is marketed by Amedra Pharmaceuticals (a subsidiary of Impax/Amneal).

Key availability observations:

• Chain pharmacies frequently do not stock Albendazole routinely and may need to special-order it (1–3 business day turnaround if the distributor has supply).
• Independent and specialty pharmacies — particularly those serving infectious disease practices or immigrant health clinics — are more likely to maintain regular stock.
• Hospital outpatient pharmacies often keep Albendazole available for patients seen in infectious disease or tropical medicine clinics.
• Mail-order pharmacies may have supply when local pharmacies do not, though shipping times can delay treatment initiation.

Cost and Access Considerations

Cost can be a significant barrier to treatment adherence, particularly for uninsured or underinsured patients:

• Retail cash price: $150–$546 for 4 tablets (200 mg each) without insurance
• Discount card price: As low as $37 for 2 tablets through programs like SingleCare and GoodRx
• Extended courses: A 28-day hydatid disease cycle (400 mg BID) requires 112 tablets, potentially costing $2,000–$15,000+ at retail
• Insurance coverage: Most plans cover generic Albendazole, though prior authorization may be required for extended courses
• Patient assistance: No manufacturer-sponsored PAP exists. Third-party services like Prescription Hope offer Albendazole at $70/month. NeedyMeds and RxAssist may list additional resources.

For a comprehensive patient-facing resource on cost reduction, see how to save money on Albendazole. For provider-specific strategies, see our provider's guide to helping patients save.

Tools and Resources for Providers

Several tools can help streamline medication access for your patients:

• Medfinder for Providers: Search for pharmacies with Albendazole in stock by location. Share results directly with patients.
• FDA Drug Shortage Database: Monitor FDA shortage listings for official updates.
• ASHP Drug Shortage Resource Center: Additional tracking and clinical guidance for shortage management.
• Discount card referrals: Direct patients to SingleCare, GoodRx, or WellRx for significant savings — these are free to use and require no insurance.

Looking Ahead

The fundamental supply-demand imbalance for Albendazole is unlikely to resolve quickly. Demand continues to grow, and the number of manufacturers remains limited. Until additional generic competitors enter the market or manufacturing capacity expands, providers should:

• Proactively verify pharmacy stock before prescribing
• Maintain awareness of alternative agents for each indication
• Help patients navigate cost barriers with discount programs
• Consider referring complex cases to infectious disease specialists who may have established relationships with specialty pharmacies

Final Thoughts

Albendazole remains indispensable for treating hydatid disease, neurocysticercosis, and numerous other parasitic infections. The ongoing supply challenges require providers to be proactive — checking availability, planning for potential delays, and guiding patients toward cost-saving resources.

Medfinder for Providers is designed to help you spend less time on medication logistics and more time on patient care. For a practical workflow guide, see our article on how to help your patients find Albendazole in stock.